Suzhou Zelgen Biopharmaceuticals Co Ltd
SSE:688266

Watchlist Manager
Suzhou Zelgen Biopharmaceuticals Co Ltd Logo
Suzhou Zelgen Biopharmaceuticals Co Ltd
SSE:688266
Watchlist
Price: 64.04 CNY -4.28% Market Closed
Market Cap: 17B CNY
Have any thoughts about
Suzhou Zelgen Biopharmaceuticals Co Ltd?
Write Note

Suzhou Zelgen Biopharmaceuticals Co Ltd
Pre-Tax Income

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Suzhou Zelgen Biopharmaceuticals Co Ltd
Pre-Tax Income Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Pre-Tax Income CAGR 3Y CAGR 5Y CAGR 10Y
Suzhou Zelgen Biopharmaceuticals Co Ltd
SSE:688266
Pre-Tax Income
-ÂĄ299.1m
CAGR 3-Years
1%
CAGR 5-Years
8%
CAGR 10-Years
N/A
Beigene Ltd
HKEX:6160
Pre-Tax Income
-ÂĄ6.2B
CAGR 3-Years
18%
CAGR 5-Years
-5%
CAGR 10-Years
N/A
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SSE:603392
Pre-Tax Income
ÂĄ1.4B
CAGR 3-Years
22%
CAGR 5-Years
37%
CAGR 10-Years
N/A
Shanghai RAAS Blood Products Co Ltd
SZSE:002252
Pre-Tax Income
ÂĄ2.2B
CAGR 3-Years
9%
CAGR 5-Years
N/A
CAGR 10-Years
23%
Chongqing Zhifei Biological Products Co Ltd
SZSE:300122
Pre-Tax Income
ÂĄ7B
CAGR 3-Years
-6%
CAGR 5-Years
25%
CAGR 10-Years
47%
Imeik Technology Development Co Ltd
SZSE:300896
Pre-Tax Income
ÂĄ2.2B
CAGR 3-Years
62%
CAGR 5-Years
72%
CAGR 10-Years
N/A
No Stocks Found

Suzhou Zelgen Biopharmaceuticals Co Ltd
Glance View

Market Cap
17B CNY
Industry
Biotechnology

Suzhou Zelgen Biopharmaceuticals Co., Ltd. engages in the innovation, research, development, manufacturing, and commercialization of new medications. The company is headquartered in Suzhou, Jiangsu and currently employs 688 full-time employees. The company went IPO on 2020-01-23. The firm's main technology platforms include precision small molecule drugs R & D and industrialization platform and complex recombinant protein drug development and industrialization platform. The firm's R & D product pipelines include Donafenib, Recombinant human thrombin for topical use, Jaktinib hydrochloride tablets, Alkotinib, Recombinant human thyroid stimulating hormone for injection, Jaktinib hydrochloride cream, ZG5266, ZG0588, ZG170607, double Specific antibodies ZG005 and ZG006. The firm also provides R & D and clinical trial drug production and processing services. The firm operates its businesses primarily in Mainland China.

Intrinsic Value
57.58 CNY
Overvaluation 10%
Intrinsic Value
Price

See Also

What is Suzhou Zelgen Biopharmaceuticals Co Ltd's Pre-Tax Income?
Pre-Tax Income
-299.1m CNY

Based on the financial report for Dec 31, 2023, Suzhou Zelgen Biopharmaceuticals Co Ltd's Pre-Tax Income amounts to -299.1m CNY.

What is Suzhou Zelgen Biopharmaceuticals Co Ltd's Pre-Tax Income growth rate?
Pre-Tax Income CAGR 5Y
8%

Over the last year, the Pre-Tax Income growth was 39%. The average annual Pre-Tax Income growth rates for Suzhou Zelgen Biopharmaceuticals Co Ltd have been 1% over the past three years , 8% over the past five years .

Back to Top